{"id":"W4403320599","doi":"10.1212/nxi.0000000000200321","title":"Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis","year":2024,"lang":"en","type":"article","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"UCB Pharma; Sanofi Genzyme; EMD Serono; Genentech; Biogen; Celgene; Alexion Pharmaceuticals; Shionogi; Sanofi; Teva Pharmaceutical Industries; Bristol-Myers Squibb; Eli Lilly and Company","keywords":"Dosing; Natalizumab; Multiple sclerosis; Pharmacodynamics; Pharmacokinetics; Medicine; Relapsing remitting; Pharmacology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002778557,0.00043391,0.0006762183,0.0005632554,0.0002903905,0.00007215807,0.0001811941,0.0003715869,0.00001940583],"category_scores_gemma":[0.000660161,0.000436716,0.0002562852,0.0004093745,0.0005559984,0.0002957018,0.0001545843,0.0009278855,0.00001038984],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003238429,"about_ca_system_score_gemma":0.000132835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002100879,"about_ca_topic_score_gemma":0.000002555732,"domain_scores_codex":[0.9970386,0.0002889521,0.0009688449,0.0008526809,0.0002291788,0.0006217617],"domain_scores_gemma":[0.9976149,0.001305339,0.0003739594,0.0003835854,0.0001789121,0.0001433377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.00366565,0.0002744407,0.002652045,0.0005191366,0.0002251314,0.0002668583,0.0002471347,0.0002702943,0.9679989,0.0003348937,0.0002369619,0.02330853],"study_design_scores_gemma":[0.02193124,0.008112032,0.1935462,0.001321765,0.003998388,0.004629321,0.00006508,0.5350588,0.2156666,0.0005821399,0.01394209,0.001146352],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866702,0.00556314,0.000588801,0.003328659,0.002067097,0.001110419,0.00007904699,0.0004388794,0.0001537834],"genre_scores_gemma":[0.9957814,0.002484162,0.0003145645,0.0008268326,0.0002028631,0.00004709544,0.0001155553,0.0001358931,0.00009169296],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7523323,"threshold_uncertainty_score":0.9998085,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0320156708101307,"score_gpt":0.2740794635867067,"score_spread":0.242063792776576,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}